CSIMarket Company Name, Ticker, Customers, else..
 
Accustem Sciences Inc   (ACUT)
Other Ticker:  
 
 
Price: $0.4500 $-0.01 -2.174%
Day's High: $0.498 Week Perf: -10 %
Day's Low: $ 0.45 30 Day Perf: 87.5 %
Volume (M): 4 52 Wk High: $ 0.67
Volume (M$): $ 2 52 Wk Avg: $0.37
Open: $0.45 52 Wk Low: $0.22



 Market Capitalization (Millions $) 5
 Shares Outstanding (Millions) 11
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -1
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Accustem Sciences Inc
Accustem Sciences Inc is a company that specializes in the development and commercialization of innovative diagnostics and therapies for cancer patients. Their focus is on personalized medicine, using genetic information to tailor treatments to individual patients.

The company utilizes advanced technologies to analyze genomic and proteomic data, providing insights into disease mechanisms and treatment options. They also offer prognostic and diagnostic tests to aid in the early detection and monitoring of cancer.

Accustem Sciences Inc aims to improve patient outcomes by providing physicians with targeted therapies that have a higher likelihood of success. Their research and development efforts are focused on identifying new drug targets and developing companion diagnostics to optimize treatment efficacy.

The company collaborates with academic institutions, pharmaceutical companies, and healthcare organizations to further its research and expand its product portfolio. Their ultimate goal is to make personalized medicine accessible to a wider population, ultimately improving the quality of care for cancer patients.


   Company Address: 5 Penn Plaza #1954 New York 10001 NY
   Company Phone Number: 2074952379   Stock Exchange / Ticker: ACUT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
DGX   -0.24%    
EXAS        1.45% 
GH   -2.8%    
NEO   -5.24%    
NTRA        0.14% 
• View Complete Report
   



Accustem Sciences Inc

Major Pharmaceutical Preparations Company, Accustem Sciences Inc, Makes Striking Progress with Reduced Operating Shortfall in Q2 2023



The earnings season for the period of April to June 30, 2023, has unveiled interesting developments in the stock market, particularly in the Major Pharmaceutical Preparations industry. Accustem Sciences Inc, a prominent player in the industry, has recently reported an operating shortfall of $-0.372756 million for the most recent fiscal period. This announcement has garnered attention due to the significant progress observed compared to the same period last year. Market observers are finding assurance in these positive indicators, setting the stage for continued growth and potential success for Accustem Sciences Inc.
Reduced Operating Shortfall:
One of the noteworthy aspects of Accustem Sciences Inc's earnings report is the obvious improvement in the operating shortfall. In the previous fiscal period, the company reported a figure of $-1.078226 million, which saw a remarkable decrease to $-0.372756 million for the current period. This reduction in the operating shortfall demonstrates that Accustem Sciences Inc has taken positive steps towards profitability, providing investors and market analysts with confidence in the company's future prospects.
Accustem Sciences Inc

Accustem Sciences Inc. Faces Operating Shortfall in Fiscal First Quarter of 2023, Industry Analysts Concerned

In the world of finance, there is no shortage of news and analysis. And for those who follow the Major Pharmaceutical Preparations sector, the first quarter of 2023 has been especially noteworthy. Analysts and consultants have been busy scrutinizing the earnings reports of the leading players in the industry, trying to get a sense of what's driving growth and where there may be areas of concern.
One company that has garnered a lot of attention is Accustem Sciences Inc. According to recent reports, the company has posted an operating shortfall of $-0.833341 million for the first quarter of 2023. Unlike some of its competitors, however, Accustem Sciences has not yet disclosed its top-line figures, leaving some analysts scrambling to fill in the gaps.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com